公开(公告)号：US12146187B2

公开(公告)日：2024-11-19

申请号：US16311001

申请日：2017-06-19

Applicant: NOVARTIS AG

Inventor： Yunsheng He ,  Christian Leisner ,  Michael Wald ,  Georges Weissgerber

IPC: C12Q1/68 ,  C12Q1/6827 ,  C12Q1/6858 ,  C12Q1/6883 ,  A61K38/00 ,  A61P27/02 ,  C07K16/24

Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFα antagonist, e.g., a TNFα antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFα antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636.

公开(公告)号：US20190177407A1

公开(公告)日：2019-06-13

申请号：US16311001

申请日：2017-06-19

Applicant: NOVARTIS AG

Inventor： Yunsheng He ,  Christian Leisner ,  Michael Wald ,  Georges Weissberber

IPC: C07K16/24 ,  A61P27/02 ,  C12Q1/6827 ,  C12Q1/6858

Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFα antagonist, e.g., a TNFα antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFα antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636.

公开(公告)号：US20250129414A1

公开(公告)日：2025-04-24

申请号：US18921747

申请日：2024-10-21

Applicant: NOVARTIS AG

Inventor： Yunsheng He ,  Christian Leisner ,  Michael Wald ,  Georges Weissgerber

IPC: C12Q1/6858 ,  A61K38/00 ,  A61P27/02 ,  C07K16/24 ,  C12Q1/6827 ,  C12Q1/6883

Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFα antagonist, e.g., a TNFα antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFα antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636.